Topiramate Adjunctive Therapy for Olanzapine Induced Weight Gain in Patients with Schizophrenia

  • Sanjib Pandit Lecturer, Department of Psychiatry, Karnali Academy of Health Sciences Jumla Nepal
  • Asha Sharma Medical Officer, Karnali Academy of Health Sciences (KAHS), Jumla, Nepal


In recent days, the prevailing use of second-generation antipsychotics (SGA) or atypical antipsychotics over conventional antipsychotics have shifted the concern of physician from extrapyramidal side effects to the weight gain in the patients receiving treatment for schizophrenia. Among others atypical anti-psychotics, the phenomenology of Olanzapine related weight gain is highly recognized in the clinical practice. However, the exact mechanism by which Olanzapine exerts weight gain effect is largely not understood and is very likely to be multi-factorial. Among other several risk factors, factors such as 5HT2c polymorphisms and H1 receptor affinity have also been purposed. Similarly, various neuro-endocrinal factors related in maintaining energy homeostasis have also been observed to be affected by Olanzapine treatment. However, no consistent findings are available to clearly explain the underlying psychopathology of disease spectrum in schizophrenia. However, though, recent finding from a clinical trial carried out in healthy male volunteers have suggested that the low baseline TSH profile predicts Olanzapine related weight gain and also interestingly relief by Topiramate adjuvant therapy. However, no such investigations were found in a schizophrenic patient.

Keywords: Topiramate, Olanzapine, Weight Gain, Schizophrenia


How to Cite
Pandit S, Sharma A. Topiramate Adjunctive Therapy for Olanzapine Induced Weight Gain in Patients with Schizophrenia. JKAHS [Internet]. 13Aug.2019 [cited 30May2020];2(2). Available from:
Review Articles